Reducing Infusion Delays With Better Supply Flow
For clinical teams, reducing infusion delays with better supply flow depends on supply habits that stay organized when patient care ...
Reducing Chemical Risk in Pathology Labs
Pathology work depends on precision, even so that precision begins before a specimen reaches the microscope. Chemical handling influences air ...
How Rural Clinics Can Prepare for Crisis Transfers
Rural clinics often face situations where a routine patient visit quickly turns into an urgent transfer. Limited staffing, unpredictable weather, ...
How To Reduce Transfer Stress in Clinics
If you work in a clinic, you know that patient transfers can set the tone for the entire visit. When ...
How the Use of Sedation in Dentistry Has Changed Over Time
Dental professionals have been using sedation in their practices for centuries. But what that sedation looked like has changed dramatically ...
How To Reduce Chemical Risks in Facility Cleaning
Facility cleaning supports infection control, workplace hygiene, and public confidence. Yet cleaning products can pose exposure risks when teams overlook ...
When Hospitals Can Be Liable for Abusive Providers
When a medical provider abuses a patient, it’s clear that they’re liable for the harm they caused. But could the ...
Growth Hormone Secretagogues and the Longevity Trade-Off
Longevity medicine is a field in the process of inventing itself — assembling, from the raw material of geroscience, a ...
Testosterone, HGH, and the Industrial Logic of Male Optimization
Testosterone replacement therapy has been practiced in some form since the 1940s, and the clinical indications for it — classical ...
The Peptide Underground: Clinical Evidence, Compounding Markets, and the Optimization Economy
The peptide optimization market exists in a regulatory and evidentiary gap that is unusual even by the standards of the ...
GLP-1 Agonists Beyond Obesity: The Expanding Therapeutic and Optimization Frontier
The SELECT trial's results, published in 2023, established something that the GLP-1 agonist's mechanistic profile had long suggested but clinical ...
Carve-Outs, Coalitions, and the New Architecture of Employer Pharmacy
The traditional employer pharmacy benefit structure — select a PBM, sign a contract, delegate formulary management — has not disappeared. ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more